knowledge -WSS

knowledge

author：focus 2025-09-29 01:38:17 - browse：22

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： World's first CRISPR

explore

WSS

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Health and fitness trackers are measuring the wrong things

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Weight loss drug costs may need more research, senator suggests

Gain of function research would be limited under House proposal

Astellas still sees hope in its gene therapy after four deaths

entertainment

knowledge

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Childhood cancer progress stalls for Black, Hispanic kids: Report

The cancer drug shortage isn’t new — and neither are the solutions

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Guidelines to prevent youth baseball injuries need more muscle

Generative AI mines health records to identify patients’ social needs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Generative AI mines health records to identify patients’ social needs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

hotspot

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Idaho abortion case may prompt more restrictions in other states

Wegovy, Zepbound and weight loss drugs that preserve muscle

Generative AI mines health records to identify patients’ social needs

CRISPR pioneers react to Casgevy, first gene

Three issues to watch in global health in 2024

explore

focus

Wikipedia

focus